Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 9/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 7/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.35 |
| ▸ | CDK7 | P50613 | 4/20 | 0.35 |
| ▸ | CDK9 | P50750 | 4/20 | 0.35 |
| ▸ | CCNH | P51946 | 4/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.33 |
| ▸ | NEK2 | P51955 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1957754 | 1.00 | BRD4 (0.39) | BRD4SCN9ACNR2CDK2CCNA2 | |
| SCHEMBL1957755 | 1.00 | BRD4 (0.39) | BRD4SCN9ACNR2CDK2CCNA2 | |
| SCHEMBL1700480 | 0.89 | BRD4 (0.43) | BRD4SCN9ACNR2CDK2CCNA2 | |
| SCHEMBL31286227 | 0.89 | BRD4 (0.43) | BRD4SCN9ACNR2CDK2CCNA2 | |
| SCHEMBL1700477 | 0.89 | BRD4 (0.43) | BRD4SCN9ACNR2CDK2CCNA2 | |
| SCHEMBL1700479 | 0.89 | BRD4 (0.43) | BRD4SCN9ACNR2CDK2CCNA2 | |
| SCHEMBL1700611 | 0.84 | SCN9A (0.43) | BRD4SCN9ACDK2CCNA2CCNA1 | |
| SCHEMBL1700454 | 0.79 | BRD4 (0.44) | BRD4SCN9ACDK2CCNA2CCNA1 | |
| SCHEMBL1700968 | 0.79 | BRD4 (0.44) | BRD4SCN9ACDK2CCNA2CCNA1 | |
| SCHEMBL1700455 | 0.79 | BRD4 (0.44) | BRD4SCN9ACDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507229-B1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9073855-B2 | BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9045420-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140107119-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8586754-B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | BRD4 203/4885SCN9A 4489/4885CNR2 2764/4885 |
| US-20140107119-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | BRD4 155/4885SCN9A 4475/4885CNR2 2729/4885 |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | BRD4 155/4885SCN9A 4475/4885CNR2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.